Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 855-861

  Saigusa, Susumu ^a   Tanaka, Koji ^a   Toiyama, Yuji ^a   Matsushita, Kohei ^a   Kawamura, Mikio ^a   Okugawa, Yoshinaga ^a   Hiro, Junichiro ^a   Inoue, Yasuhiro ^a   Uchida, Keiichi ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene expression profiles; Neoadjuvant chemoradiotherapy; Rectal cancer; Tumor regression grade

Indexed keywords

FLUOROURACIL; TEGAFUR;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BAX GENE; CANCER GRADING; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CD44 GENE; CDK2 GENE; CDKN1A GENE; CHEK1 GENE; EGFR GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUT1 GENE; HGF GENE; HIF1 GENE; HUMAN; LGR5 GENE; LIVER METASTASIS; LKB1 GENE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MET GENE; MK167 GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PCNA GENE; PDRG1 GENE; PERITONEUM METASTASIS; POU5F1 GENE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROM1 GENE; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOX2 GENE; TREATMENT RESPONSE; TUMOR REGRESSION GRADING; VEGF GENE;

ADENOCARCINOMA; ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; CHEMORADIOTHERAPY; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE TRANSPORTER TYPE 1; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RECTAL NEOPLASMS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865317958     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1863     Document Type: Article

References (41)

1. Van den Brink M, Stiggelbout AM, van den Hout WB, et al: Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 22: 3958-3964, 2004.
2. Collette L, Bosset JF, den Dulk M, et al: Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25: 4379-4386, 2007.
3. Rodel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696, 2005.
4. Vironen J, Juhola M, Kairaluoma M, et al: Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis 20: 440-445, 2005.
5. Vecchio FM, Valentini V, Minsky BD, et al: The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62: 752-760, 2005.
6. Bujko K, Michalski W, Kepka L, et al: Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67: 369-377, 2007.
7. Dhadda AS, Dickinson P, Zaitoun AM, et al: Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. Eur J Cancer 47: 1138-1145, 2011.
8. Topova L, Hellmich G, Puffer E, et al: Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum 54: 401-411, 2011.
9. Jorgensen TJ: Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 8: 665-670, 2009.
10. Maity A, McKenna WG and Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 31: 1-13, 1994.
11. Coleman CN: Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80: 310-317, 1988.
12. Overgaard J: Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25: 4066-4074, 2007.
13. Deorukhkar A and Krishnan S: Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 80: 1904-1914, 2010.
14. Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554, 2008.
15. Zeki SS, Graham TA and Wright NA: Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 8: 90-100, 2011.
16. Yoshikawa R, Kusunoki M, Yanagi H, et al: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001.
17. Bateman AC, Jaynes E and Bateman AR: Rectal cancer staging post neoadjuvant therapy - how should the changes be assessed? Histopathology 54: 713-721, 2009.
18. Japanese Society for Cancer of the Colon and Rectum: General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Kanehara & Co., Tokyo, 2006.
19. Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73: 2680-2686, 1994.
20. Dworak O, Keilholz L and Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12: 19-23, 1997.
21. Saigusa S, Tanaka K, Toiyama Y, et al: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16: 3488-3498, 2009.
22. Bijwaard KE, Aguilera NS, Monczak Y, et al: Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47: 195-201, 2001.
23. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
24. Gerard JP, Chapet O, Nemoz C, et al: Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 22: 2404-2409, 2004.
25. Guillem JG, Chessin DB, Cohen AM, et al: Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241: 829-838, 2005.
26. Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355: 1114-1123, 2006.
27. Kaminsky-Forrett MC, Conroy T, Luporsi E, et al: Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys 42: 935-941, 1998.
28. Chapet O, Romestaing P, Mornex F, et al: Preoperative radiotherapy for rectal adenocarcinoma: which are strong prognostic factors? Int J Radiat Oncol Biol Phys 61: 1371-1377, 2005.
29. Kim TH, Chang HJ, Kim DY, et al: Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 77: 1158-1165, 2010.
30. Barker N, van Es JH, Kuipers J, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007, 2007.
31. Uchida H, Yamazaki K, Fukuma M, et al: Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 101: 1731-1737, 2010.
32. Luo X, Huang Y and Sheikh MS: Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation. Oncogene 22: 7247-7257, 2003.
33. Jiang L, Luo X, Shi J, et al: PDRG1, a novel tumor marker for multiple malignancies that is selectively regulated by genotoxic stress. Cancer Biol Ther 11: 567-573, 2011.
34. Chung FY, Huang MY, Yeh CS, et al: GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer 9: 241, 2009.
35. Brophy S, Sheehan KM, McNamara DA, et al: GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer 125: 2778-2782, 2009.
36. Hofstadter F, Knuchel R and Ruschoff J: Cell proliferation assessment in oncology. Virchows Arch 427: 323-341, 1995.
37. Herrmann JL, Byekova Y, Elmets CA, et al: Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett 306: 1-9, 2011.
38. Gurumurthy S, Xie SZ, Alagesan B, et al: The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 468: 659-663, 2010.
39. Gan B, Hu J, Jiang S, et al: Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468: 701-704, 2010.
40. Yamaguchi H, Bhalla K and Wang HG.: Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res 63: 1483-1489, 2003.
41. Chang HJ, Jung KH, Kim DY, et al: Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 36: 364-371, 2005.